Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
Immune checkpoint inhibitors enrich the therapeutic landscape in oesophago-gastric carcinoma. With regard to oesophageal squamous cell carcinoma (ESCC), the selective PD-1 (programmed cell death receptor 1)-inhibitor nivolumab improves disease-free survival in the adjuvant therapy setting (CHECKMATE...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2021-02-01
|
| Seri Bilgileri: | Pharmaceuticals |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1424-8247/14/2/151 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|